Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

A Thorough Analysis of Global Racial Disparities in HBV Care

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Released: December 10, 2021
Back Next

References

  1. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383-403.
  2. Coppola N, Alessio L, Pisaturo M, et al. Hepatitis B virus infection in immigrant populations. World J Hepatol. 2015;7:2955-2961.
  3. Jones P, Soler J, Schaefer Solle N, et al. A mixed-methods approach to understanding perceptions of hepatitis B and hepatocellular carcinoma among ethnically diverse Black communities in South Florida. Cancer Causes Control. 2020;3:1079-1091.
  4. Mohamed EA, Giama NH, Shaleh HM, et al. Knowledge, attitudes, and behaviors of viral hepatitis among recent African immigrants in the United States: A community based participatory research qualitative study. Front Public Health. 2020;8:25.
  5. Kim LH, Nguyen VG, Trinh HN, et al. Low treatment rates in patients meeting guideline criteria in diverse practice settings. Dig Dis Sci. 2014;59:2091-2099.
  6. Mokaya J, McNaughton AL, Burbridge L, et al. A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection—a systematic review. Wellcome Open Res. 2018;3:29.
  7. Ogawa E, Yeo YH, Dang N, et al. Diagnosis rates of chronic hepatitis B in privately insured patients in the United States. JAMA Netw Open. 2020;3:e201844.
Back Next
Provided by Clinical Care Options. LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings